1. Home
  2. ISPC vs GNPX Comparison

ISPC vs GNPX Comparison

Compare ISPC & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iSpecimen Inc.

ISPC

iSpecimen Inc.

HOLD

Current Price

$0.46

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.72

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISPC
GNPX
Founded
2009
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
6.5M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
ISPC
GNPX
Price
$0.46
$2.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
446.6K
322.7K
Earning Date
11-17-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,352,744.00
N/A
Revenue This Year
$35.93
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$2.61
52 Week High
$4.66
$63.00

Technical Indicators

Market Signals
Indicator
ISPC
GNPX
Relative Strength Index (RSI) 37.74 41.51
Support Level $0.39 $3.15
Resistance Level $0.53 $3.68
Average True Range (ATR) 0.07 0.28
MACD 0.02 -0.00
Stochastic Oscillator 23.13 21.38

Price Performance

Historical Comparison
ISPC
GNPX

About ISPC iSpecimen Inc.

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: